Navigation Links
Novel export-inhibitor shows promise for treating CLL
Date:12/12/2011

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The agent, called KPT-SINE, belongs to a new class of drugs called selective inhibitors of nuclear export (SINE). The agent was developed by Karyopharm Therapeutics Inc. It is designed to kill cancer cells by restoring biochemical pathways that normally cause unhealthy cells to self-destruct through a process called programmed cell death, or apoptosis.

The agent targets a protein called CRM1, which, until now, has not been adequately explored in CLL, the researchers say. During disease progression, cancer cells use CRM1 to shunt certain apoptosis-related proteins out of the nucleus, thereby avoiding cell death.

"We believe that KPT-SINE and other nuclear-export inhibitors may represent a unique, entirely new therapeutic strategy for treating cancer by simultaneously restoring multiple normal cell death pathways," says OSUCCC James research scientist Dr. Rosa Lapalombella who is a co-investigator on the study with Dr. John Byrd, director of the division of hematology and co-director of the OSUCCC James CLL Experimental Therapeutics Laboratory at OSUCCC James.

The researchers hypothesize that KPT-SINE will inhibit CRM1 and keep these regulatory proteins in the nucleus where they can initiate programmed cell death.

Lapalombella will discuss the role of CRM1 inhibition in the treatment of CLL on Monday, December 12, at 7:00 a.m. during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

The study, which used CLL cells from patients and a mouse model of CLL, provides essential proof-of-concept data to desig
'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Novel experimental agent is highly active in CLL patients, interim study shows
2. Researchers identify a novel therapeutic approach for liver cancer
3. Novel drug wipes out deadliest malaria parasite through starvation
4. Novel approach to treating breast cancer shows great promise
5. Wayne State receives $1.9 million from NIH to create novel cystic fibrosis treatments
6. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
7. Wayne State University to study novel treatment for antibiotic-resistant bacteria
8. Novel, noninvasive measurement a strong predictor for heart failure in general population
9. UK HealthCare surgeons are first to perform novel procedures prior to transplant
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. Novel strategy stymies SARS et al.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... ProvidaStaff has announced today that it is changing ... EDU Healthcare to reflect better on the commitment ... nationwide. , “ProvidaStaff has always been a leading healthcare ... Angela M. Lewis, President of ProvidaStaff. “We continue to ... of EDU Healthcare better aligns our services to our ...
(Date:3/2/2015)... 02, 2015 Secura Consultants announced ... with First Protective Insurance Group of Birmingham, AL ... First Protective affiliated advisors to access the enhanced ... Secura Consultants delivers. , Secura Consultants, ... in the design and implementation of insured income ...
(Date:3/1/2015)... 2015 As residents and business ... Michael Burns and Carita Weaver, believe in supporting ... with the Southlake Chamber of Commerce, Carroll Independent ... recently launched a website for Southlake mayoral candidate ... communications tool for Hill’s campaign, the website combines ...
(Date:3/1/2015)... 01, 2015 Comparing a new source ... using the Quotes Pros portal this year. A broad ... insurance rates that are being supplied through the finder ... agencies and prices available for each policy is now ... Every system user will first be asked to present ...
Breaking Medicine News(10 mins):Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:United Auto Insurance Rates Now Quoted at Consumer Insurance Portal Online 2
... families are involved, study finds , FRIDAY, June 12 ... of an incurable genetic disease isn,t worry enough, people ... discriminated against by insurance companies, relatives and in social ... and colleagues at the University of British Columbia surveyed ...
... , ATLANTA, June 12 Salient Mobility LLC, ... of the 2009 " Text For a Cause(TM) " campaign, ... from organizations such as the Georgia Cancer Foundation . ... campaign begins August 24th, and culminates with the issuance of ...
... 12 June 2009: Three new studies have individually shown ... effective, with a good safety profile, in children under ... and associated with improved Health-Related Quality of Life (HRQoL) ... data are being presented at the Paediatric Rheumatology European ...
... five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% ... benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ... AS patients had no arthritis and 84.9% had no ... Over this period, patients continued to show a sustained ...
... National Quality Forum (NQF) has tapped Thomas B. Valuck, ... Strategic Partnerships. Dr. Valuck comes to NQF from the ... was both Medical Officer and Senior Adviser in the ... a unique, multi-stakeholder, nonprofit organization dedicated to improving the ...
... Medifast, Inc. (NYSE: MED ) today announced ... corporate-owned Medifast Weight Control Centers. Earlier in the year, the ... out, and analyze the success of the model throughout the ... be expanding its investment in this area. , , ...
Cached Medicine News:Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Salient Mobility Launches the 'Text For a Cause(TM)' Campaign in Raising Awareness Through Wireless Health Tips 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 2Health News:National Quality Forum Welcomes Dr. Thomas Valuck, SVP of Strategic Partnerships 3Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced financial results for its first ... the three months ended December 31, 2014, revenue was ... quarter was $229,820 or $0.02 per share.  ... said "I am very pleased with the significant progress ...
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Finesse Solutions announced the expansion of its operations in ... planned for mid-March and access for customers is expected ... A-563, and located adjacent to the current office, the ... Finesse automation engineering team and allow Finesse to bring on ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2
... , PLYMOUTH MEETING, Pa., Nov. 20 ... article that questions why currently available medications designed to treat and ... organization, is offering a roadmap to the evidence on Finasteride ... , The November 13, 2009, New York Times article, ...
... , PRINCETON, N.J., Nov. 20 Soligenix, ... formerly known as DOR BioPharma, Inc., a late-stage biotechnology ... to develop thermostable technology to advance RiVax(TM) and other ... from the National Institute of Allergy and Infectious Diseases ...
Cached Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
...
... a cutting-edge ECG management system ... and convenient, web-based access to ... information technology (IT) benefits, resulting ... and improved patient care. ...
Medicine Products: